Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2013

Open Access 01-12-2013 | Research

Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain

Authors: Maj-Linda B Selenica, Jennifer A Alvarez, Kevin R Nash, Daniel C Lee, Chuanhai Cao, Xiaoyang Lin, Patrick Reid, Peter R Mouton, Dave Morgan, Marcia N Gordon

Published in: Journal of Neuroinflammation | Issue 1/2013

Login to get access

Abstract

Background

The chemokine (C-C motif) ligand 2 (CCL2) is a monocyte chemoattractant protein that mediates macrophage recruitment and migration during peripheral and central nervous system (CNS) inflammation.

Methods

To determine the impact of CCL2 in inflammation in vivo and to elucidate the CCL2-induced polarization of activated brain microglia, we delivered CCL2 into the brains of wild-type mice via recombinant adeno-associated virus serotype 9 (rAAV-9) driven by the chicken β-actin promoter. We measured microglial activation using histological and chemical measurement and recruitment of monocytes using histology and flow cytometry.

Results

The overexpression of CCL2 in the CNS induced significant activation of brain resident microglia. CD45 and major histocompatibility complex class II immunoreactivity significantly increased at the sites of CCL2 administration. Histological characterization of the microglial phenotype revealed the elevation of “classically activated” microglial markers, such as calgranulin B and IL-1β, as well as markers associated with “alternative activation” of microglia, including YM1 and arginase 1. The protein expression profile in the hippocampus demonstrated markedly increased levels of IL-6, GM-CSF and eotaxin (CCL-11) in response to CCL2, but no changes in the levels of other cytokines, including TNF-α and IFN-γ. Moreover, real-time PCR analysis confirmed increases in mRNA levels of gene transcripts associated with neuroinflammation following CCL2 overexpression. Finally, we investigated the chemotactic properties of CCL2 in vivo by performing adoptive transfer of bone marrow–derived cells (BMDCs) isolated from donor mice that ubiquitously expressed green fluorescent protein. Flow cytometry and histological analyses indicated that BMDCs extravasated into brain parenchyma and colabeled with microglial markers.

Conclusion

Taken together, our results suggest that CCL2 strongly activates resident microglia in the brain. Both pro- and anti-inflammatory activation of microglia were prominent, with no bias toward the M1 or M2 phenotype in the activated cells. As expected, CCL2 overexpression actively recruited circulating monocytes into the CNS. Thus, CCL2 expression in mouse brain induces microglial activation and represents an efficient method for recruitment of peripheral macrophages.
Literature
1.
Chen Y, Hallenbeck JM, Ruetzler C, Bol D, Thomas K, Berman NE, Vogel SN: Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab 2003, 23:748–755.CrossRefPubMed
2.
Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE: Amyloid-β induces chemokine secretion and monocyte migration across a human blood–brain barrier model. Mol Med 1998, 4:480–489.PubMedPubMedCentral
3.
Fuentes ME, Durham SK, Swerdel MR, Lewin AC, Barton DS, Megill JR, Bravo R, Lira SA: Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J Immunol 1995, 155:5769–5776.PubMed
4.
Glabinski AR, Tani M, Tuohy VK, Tuthill RJ, Ransohoff RM: Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. Brain Behav Immun 1995, 9:315–330.CrossRefPubMed
5.
Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998, 2:275–281.CrossRefPubMed
6.
Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, Burdick MD, Pope RM, Strieter RM: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992, 90:772–779.CrossRefPubMedPubMedCentral
7.
8.
Prinz M, Priller J: Tickets to the brain: role of CCR2 and CX 3 CR 1 in myeloid cell entry in the CNS. J Neuroimmunol 2010, 224:80–84.CrossRefPubMed
9.
Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Brück W, Priller J, Prinz M: Microglia in the adult brain arise from Ly-6C hi CCR2 + monocytes only under defined host conditions. Nat Neurosci 2007, 10:1544–1553.CrossRefPubMed
10.
Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM: Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 2001, 193:713–726.CrossRefPubMedPubMedCentral
11.
Berman JW, Guida MP, Warren J, Amat J, Brosnan CF: Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat. J Immunol 1996, 156:3017–3023.PubMed
12.
Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, Gallo RC, Major EO: Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A 1998, 95:3117–3121.CrossRefPubMedPubMedCentral
13.
Mahad DJ, Ransohoff RM: The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 2003, 15:23–32.CrossRefPubMed
14.
McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF: MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998, 86:20–29.CrossRefPubMed
15.
Simard AR, Soulet D, Gowing G, Julien JP, Rivest S: Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron 2006, 49:489–502.CrossRefPubMed
16.
El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD: Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007, 13:432–438.CrossRefPubMed
17.
Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT: CX3CR1 deficiency alters microglial activation and reduces β-amyloid deposition in two Alzheimer’s disease mouse models. Am J Pathol 2010, 177:2549–2562.CrossRefPubMedPubMedCentral
18.
Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA: Blocking TGF-β-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 2008, 14:681–687.PubMedPubMedCentral
19.
Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T: CCL2 accelerates microglia-mediated Aβ oligomer formation and progression of neurocognitive dysfunction. PLoS One 2009, 4:e6197.CrossRefPubMedPubMedCentral
20.
Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006, 12:1005–1015.PubMed
21.
Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B, Scalabrini D, Clerici F, Mariani C, Bresolin N, Scarpini E: Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease. Neurobiol Aging 2006, 27:1763–1768.CrossRefPubMed
22.
Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T: Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psychiatry Clin Neurosci 1997, 51:135–138.CrossRefPubMed
23.
Lawson LJ, Perry VH, Dri P, Gordon S: Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151–170.CrossRefPubMed
24.
Kraft AD, McPherson CA, Harry GJ: Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. Neurotoxicology 2009, 30:785–793.CrossRefPubMedPubMedCentral
25.
Streit WJ, Graeber MB, Kreutzberg GW: Functional plasticity of microglia: a review. Glia 1988, 1:301–307.CrossRefPubMed
26.
27.
28.
Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677–686.CrossRefPubMed
29.
Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front Biosci 2008, 13:453–461.CrossRefPubMed
30.
Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999, 103:773–778.CrossRefPubMedPubMedCentral
31.
Gonzalo JA, Lloyd CM, Wen D, Albar JP, Wells TN, Proudfoot A, Martinez-A C, Dorf M, Bjerke T, Coyle AJ, Gutierrez-Ramos JC: The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998, 188:157–167.CrossRefPubMedPubMedCentral
32.
Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ: Control of T H 2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000, 404:407–411.CrossRefPubMed
33.
Elhofy A, Wang J, Tani M, Fife BT, Kennedy KJ, Bennett J, Huang D, Ransohoff RM, Karpus WJ: Transgenic expression of CCL2 in the central nervous system prevents experimental autoimmune encephalomyelitis. J Leukoc Biol 2005, 77:229–237.CrossRefPubMed
34.
Karpus WJ, Kennedy KJ: MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997, 62:681–687.PubMed
35.
Carty N, Nash KR, Brownlow M, Cruite D, Wilcock D, Selenica ML, Lee DC, Gordon MN, Morgan D: Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PLoS One 2013, 8:e59626.CrossRefPubMedPubMedCentral
36.
Cearley CN, Wolfe JH: A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 2007, 27:9928–9940.CrossRefPubMed
37.
Nash KR, Cardenas-Aguayo MC, Berg MJ, Marks N: Transduction of E13 murine neural precursor cells by non-immunogenic recombinant adeno-associated viruses induces major changes in neuronal phenotype. Neuroscience 2012, 210:82–98.CrossRefPubMed
38.
Zincarelli C, Soltys S, Rengo G, Rabinowitz JE: Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008, 16:1073–1080.CrossRefPubMed
39.
Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, Golde TE, Gordon MN, Morgan D, Nash K: Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods 2010, 194:144–153.CrossRefPubMedPubMedCentral
40.
Lebson L, Nash K, Kamath S, Herber D, Carty N, Lee DC, Li Q, Szekeres K, Jinwal U, Koren J, Dickey CA, Gottschall PE, Morgan D, Gordon MN: Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci 2010, 30:9651–9658.CrossRefPubMedPubMedCentral
41.
Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O’Callaghan JP, Morgan D: Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 2002, 173:183–195.CrossRefPubMed
42.
Schnell SA, Staines WA, Wessendorf MW: Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 1999, 47:719–730.CrossRefPubMed
43.
Hickman SE, Allison EK, El Khoury J: Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci 2008, 28:8354–8360.CrossRefPubMedPubMedCentral
44.
Gundersen HJ: Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsc 1986, 143:3–45.CrossRefPubMed
45.
Elomaa O, Sankala M, Pikkarainen T, Bergmann U, Tuuttila A, Raatikainen-Ahokas A, Sariola H, Tryggvason K: Structure of the human macrophage MARCO receptor and characterization of its bacteria-binding region. J Biol Chem 1998, 273:4530–4538.CrossRefPubMed
46.
Gaikwad S, Larionov S, Wang Y, Dannenberg H, Matozaki T, Monsonego A, Thal DR, Neumann H: Signal regulatory protein-β1: a microglial modulator of phagocytosis in Alzheimer’s disease. Am J Pathol 2009, 175:2528–2539.CrossRefPubMedPubMedCentral
47.
Ridinger K, Ilg EC, Niggli FK, Heizmann CW, Schäfer BW: Clustered organization of S100 genes in human and mouse. Biochim Biophys Acta 1998, 1448:254–263.CrossRefPubMed
48.
Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, Zwadlo G, Gerhards G, Schlegel R, Sorg C: Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987, 330:80–82.CrossRefPubMed
49.
Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889–901.CrossRefPubMed
50.
Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Berry MF, Burdick J, Bhalla RC, Sharma RV, Gardner TJ, Sweeney HL: Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy. Circulation 2004,110(11 Suppl 1):II180-II186.PubMed
51.
Ridnour LA, Dhanapal S, Hoos M, Wilson J, Lee J, Cheng RY, Brueggemann EE, Hines HB, Wilcock DM, Vitek MP, Wink DA, Colton CA: Nitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1. J Neurochem 2012, 123:736–749.CrossRefPubMedPubMedCentral
52.
Combs CK, Karlo JC, Kao SC, Landreth GE: β-Amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001, 21:1179–1188.PubMed
53.
Rosenfeld RG: Insulin-like growth factors and the basis of growth. N Engl J Med 2003, 349:2184–2186.CrossRefPubMed
54.
Spector EB, Rice SC, Cederbaum SD: Immunologic studies of arginase in tissues of normal human adult and arginase-deficient patients. Pediatr Res 1983, 17:941–944.CrossRefPubMed
55.
Banerjee RR, Lazar MA: Dimerization of resistin and resistin-like molecules is determined by a single cysteine. J Biol Chem 2001, 276:25970–25973.CrossRefPubMed
56.
Menzies-Gow A, Ying S, Sabroe I, Stubbs VL, Soler D, Williams TJ, Kay AB: Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 2002, 169:2712–2718.CrossRefPubMed
57.
Kitaura M, Suzuki N, Imai T, Takagi S, Suzuki R, Nakajima T, Hirai K, Nomiyama H, Yoshie O: Molecular cloning of a novel human CC chemokine (eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem 1999, 274:27975–27980.CrossRefPubMed
58.
Cormier SA, Yuan S, Crosby JR, Protheroe CA, Dimina DM, Hines EM, Lee NA, Lee JJ: T H 2-mediated pulmonary inflammation leads to the differential expression of ribonuclease genes by alveolar macrophages. Am J Respir Cell Mol Biol 2002, 27:678–687.CrossRefPubMed
59.
Lee DC, Ruiz CR, Lebson L, Selenica ML, Rizer J, Hunt JB Jr, Rojiani R, Reid P, Kammath S, Nash K, Dickey CA, Gordon M, Morgan D: Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiol Aging 2013, 34:1610–1620.CrossRefPubMedPubMedCentral
60.
Nolan T, Hands RE, Bustin SA: Quantification of mRNA using real-time RT-PCR. Nat Protoc 2006, 1:1559–1582.CrossRefPubMed
61.
Gehrmann J, Banati RB, Kreutzberg GW: Microglia in the immune surveillance of the brain: human microglia constitutively express HLA-DR molecules. J Neuroimmunol 1993, 48:189–198.CrossRefPubMed
62.
Mori T, Tan J, Arendash GW, Koyama N, Nojima Y, Town T: Overexpression of human S100B exacerbates brain damage and periinfarct gliosis after permanent focal ischemia. Stroke 2008, 39:2114–2121.CrossRefPubMedPubMedCentral
63.
Lagasse E, Weissman IL: Flow cytometric identification of murine neutrophils and monocytes. J Immunol Methods 1996, 197:139–50.CrossRefPubMed
64.
Colton CA, Wilcock DM: Assessing activation states in microglia. CNS Neurol Disord Drug Targets 2010, 9:174–191.CrossRefPubMed
65.
Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, Morgan D: Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci 2003, 23:5219–5226.PubMed
66.
Ruhul Amin AR, Machida K, Oshima K, Oo ML, Thant AA, Senga T, Matsuda S, Akhand AA, Maeda A, Kurosaki T, Hamaguchi M: A role for SHPS-1/SIRPα1 in IL-1β- and TNFα-dependent signaling. Oncogene 2002, 21:8871–8878.CrossRefPubMed
67.
Conductier G, Blondeau N, Guyon A, Nahon JL, Rovère C: The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 2010, 224:93–100.CrossRefPubMed
68.
Burger C, Nash K, Mandel RJ: Recombinant adeno-associated viral vectors in the nervous system. Hum Gene Ther 2005, 16:781–791.CrossRefPubMed
69.
Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M: Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841–845.CrossRefPubMedPubMedCentral
70.
Ransohoff RM: Microglia and monocytes: ’tis plain the twain meet in the brain. Nat Neurosci 2011, 14:1098–1100.CrossRefPubMed
71.
Gomez Perdiguero E, Schulz C, Geissmann F: Development and homeostasis of “resident” myeloid cells: the case of the microglia. Glia 2013, 61:112–120.CrossRefPubMed
72.
Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR: Analysis of fractalkine receptor CX 3 CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000, 20:4106–4114.CrossRefPubMedPubMedCentral
73.
Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou CL, Ransohoff RM, Charo IF: Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 2010, 5:e13693.CrossRefPubMedPubMedCentral
74.
Mildner A, Mack M, Schmidt H, Brück W, Djukic M, Zabel MD, Hille A, Priller J, Prinz M: CCR2 + Ly-6C hi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009, 132:2487–2500.CrossRefPubMed
75.
Schilling M, Strecker JK, Schabitz WR, Ringelstein EB, Kiefer R: Effects of monocyte chemoattractant protein 1 on blood-borne cell recruitment after transient focal cerebral ischemia in mice. Neuroscience 2009, 161:806–812.CrossRefPubMed
76.
Schellenberg AE, Buist R, Del Bigio MR, Toft-Hansen H, Khorooshi R, Owens T, Peeling J: Blood–brain barrier disruption in CCL2 transgenic mice during pertussis toxin-induced brain inflammation. Fluids Barriers CNS 2012, 9:10.CrossRefPubMedPubMedCentral
77.
Huang D, Tani M, Wang J, Han Y, He TT, Weaver J, Charo IF, Tuohy VK, Rollins BJ, Ransohoff RM: Pertussis toxin-induced reversible encephalopathy dependent on monocyte chemoattractant protein-1 overexpression in mice. J Neurosci 2002, 22:10633–10642.PubMed
78.
Bennett JL, Elhofy A, Canto MC, Tani M, Ransohoff RM, Karpus WJ: CCL2 transgene expression in the central nervous system directs diffuse infiltration of CD45 high CD11b + monocytes and enhanced Theiler’s murine encephalomyelitis virus-induced demyelinating disease. J Neurovirol 2003, 9:623–636.PubMed
79.
Trujillo JA, Fleming EL, Perlman S: Transgenic CCL2 expression in the central nervous system results in a dysregulated immune response and enhanced lethality after coronavirus infection. J Virol 2013, 87:2376–2389.CrossRefPubMedPubMedCentral
80.
Menetski J, Mistry S, Lu M, Mudgett JS, Ransohoff RM, Demartino JA, MacIntyre DE, Abbadie C: Mice overexpressing chemokine ligand 2 (CCL2) in astrocytes display enhanced nociceptive responses. Neuroscience 2007, 149:706–714.CrossRefPubMed
81.
Huang D, Wujek J, Kidd G, He TT, Cardona A, Sasse ME, Stein EJ, Kish J, Tani M, Charo IF, Proudfoot AE, Rollins BJ, Handel T, Ransohoff RM: Chronic expression of monocyte chemoattractant protein-1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice. FASEB J 2005, 19:761–772.CrossRefPubMed
82.
Matsukawa A, Lukacs NW, Standiford TJ, Chensue SW, Kunkel SL: Adenoviral-mediated overexpression of monocyte chemoattractant protein-1 differentially alters the development of Th1 and Th2 type responses in vivo. J Immunol 2000, 164:1699–1704.CrossRefPubMed
83.
Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE: Gene expression changes by amyloid β peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 2006, 79:596–610.CrossRefPubMed
84.
Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM: RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature 1996, 382:685–691.CrossRefPubMed
85.
Foell D, Frosch M, Sorg C, Roth J: Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004, 344:37–51.CrossRefPubMed
86.
Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT: Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010, 68:19–31.CrossRefPubMedPubMedCentral
87.
Naert G, Rivest S: Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Mol Med 2012, 18:297–313.CrossRefPubMed
88.
Kiyota T, Yamamoto M, Schroder B, Jacobsen MT, Swan RJ, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T: AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, β-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther 2009, 17:803–809.CrossRefPubMedPubMedCentral
89.
Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikezu T: Overexpression of monocyte chemotactic protein-1/CCL2 in β-amyloid precursor protein transgenic mice show accelerated diffuse β-amyloid deposition. Am J Pathol 2005, 166:1475–1485.CrossRefPubMedPubMedCentral
90.
Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J: Inflammatory response in the hippocampus of PS1 M146L /APP 751SL mouse model of Alzheimer’s disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 2008, 28:11650–11661.CrossRefPubMed
91.
Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O’Banion MK: Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 2007, 117:1595–1604.CrossRefPubMedPubMedCentral
92.
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT: NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493:674–678.CrossRefPubMed
93.
Bhaskar K, Yen SH, Lee G: Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem 2005, 280:35119–35125.CrossRefPubMed
94.
Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D: LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 2010, 7:56.CrossRefPubMedPubMedCentral
95.
Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE: Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer’s disease. Brain Pathol 2009, 19:392–398.CrossRefPubMed
96.
Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O: CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PLoS One 2012, 7:e30525.CrossRefPubMedPubMedCentral
Metadata
Title
Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain
Authors
Maj-Linda B Selenica
Jennifer A Alvarez
Kevin R Nash
Daniel C Lee
Chuanhai Cao
Xiaoyang Lin
Patrick Reid
Peter R Mouton
Dave Morgan
Marcia N Gordon
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2013
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-10-86

Other articles of this Issue 1/2013

Journal of Neuroinflammation 1/2013 Go to the issue

Review

Leukocyte infiltration in experimental stroke

Research

Cerebral ischemia initiates an immediate innate immune response in neonates during cardiac surgery

Research

Transmigration of polymorphnuclear neutrophils and monocytes through the human blood-cerebrospinal fluid barrier after bacterial infection in vitro

Research

Sunitinib enhances neuronal survival in vitro via NF-κB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase

Research

Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment

Research

Scolopendra subspinipes mutilans attenuates neuroinflammation in symptomatic hSOD1G93Amice